Efficacy and Safety of TLL-018 in Moderate to Severe Chronic Spontaneous Urticaria Patients with Inadequate Response to H1 Antihistamine: Results from a Phase Ib Study

Qianjin Lu,Bin Yang,Lunfei Liu,Linfeng Li,Weijun Liu,Xu Yao,Xiaoyong Man,Aijun Chen,Yuling Shi,Yangfeng Ding,Qing Sun,Juan Tao,Chris Liang,Yong Liu,Donghua Liu,Peiyu Sun
DOI: https://doi.org/10.1016/j.jaci.2023.11.891
IF: 14.29
2024-02-07
Journal of Allergy and Clinical Immunology
Abstract:To evaluate the efficacy and safety of TLL-018, a potent and selective small molecule TYK2/JAK1 inhibitor, in chronic spontaneous urticaria (CSU) adults with inadequate response to antihistamine.
immunology,allergy
What problem does this paper attempt to address?